
NRC
National Research Corp
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.910
Open
10.530
VWAP
10.67
Vol
75.05K
Mkt Cap
244.26M
Low
10.240
Amount
800.85K
EV/EBITDA(TTM)
7.13
Total Shares
23.88M
EV
302.71M
EV/OCF(TTM)
8.74
P/S(TTM)
1.78
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of three primary solution categories: Marketing, Reputation and Experience. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. The Company's Experience solutions are provided on a subscription basis via a cross-continuum multi-mode digital platform. Its Reputation solutions allow healthcare organizations to share a picture of their organization.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2019Q4
33.10M
+8.03%
0.300
0%
Estimates Revision
Stock Price
Go Down

-35.07%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for National Research Corp (NRC.O) is 9.24, compared to its 5-year average forward P/E of 34.15. For a more detailed relative valuation and DCF analysis to assess National Research Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued
5Y Average PE
34.15
Current PE
9.24
Overvalued PE
43.94
Undervalued PE
24.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued
5Y Average EV/EBITDA
22.46
Current EV/EBITDA
6.87
Overvalued EV/EBITDA
28.87
Undervalued EV/EBITDA
16.05
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued
5Y Average PS
7.61
Current PS
1.88
Overvalued PS
9.90
Undervalued PS
5.31
Financials
Annual
Quarterly
FY2024Q4
YoY :
-2.88%
36.91M
Total Revenue
FY2024Q4
YoY :
-17.88%
9.62M
Operating Profit
FY2024Q4
YoY :
-25.94%
6.56M
Net Income after Tax
FY2024Q4
YoY :
-22.22%
0.28
EPS - Diluted
FY2024Q4
YoY :
-75.62%
1.94M
Free Cash Flow
FY2024Q4
YoY :
-4.89%
57.01
Gross Profit Margin - %
FY2024Q4
YoY :
-10.84%
13.40
FCF Margin - %
FY2024Q4
YoY :
-23.77%
17.77
Net Margin - %
FY2024Q4
YoY :
-15.18%
29.78
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
8.1K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NRC News & Events
Events Timeline
2025-03-04 (ET)
2025-03-04
16:06:35
National Research Corporation names Trent Green as new CEO

2025-01-07 (ET)
2025-01-07
11:02:11
NRC Health enters partnership with Renown Health

Sign Up For More Events
Sign Up For More Events
News
2.0
04-10NewsfilterA New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience
2.0
04-10Yahoo FinanceA New Era of Trust: NRC Health’s 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience
8.0
03-24NewsfilterNational Research Corporation Declares Quarterly Dividend
Sign Up For More News
People Also Watch

VZLA
Vizsla Silver Corp
2.170
USD
-2.25%

EBS
Emergent BioSolutions Inc
5.490
USD
+2.23%

HUMA
Humacyte Inc
1.440
USD
-2.70%

TREE
Lendingtree Inc
51.540
USD
+0.02%

QD
Qudian Inc
2.650
USD
0.00%

CMTG
Claros Mortgage Trust Inc
2.430
USD
+0.83%

AMBC
Ambac Financial Group Inc
7.990
USD
+3.10%

EBF
Ennis Inc
17.920
USD
-0.78%

KULR
KULR Technology Group Inc
1.350
USD
+2.27%

TBLD
Thornburg Income Builder Opportunities Trust
17.810
USD
+0.17%
FAQ

What is National Research Corp (NRC) stock price today?
The current price of NRC is 10.72 USD — it has increased 0.23 % in the last trading day.

What is National Research Corp (NRC)'s business?

What is the price predicton of NRC Stock?

What is National Research Corp (NRC)'s revenue for the last quarter?

What is National Research Corp (NRC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for National Research Corp (NRC)'s fundamentals?

How many employees does National Research Corp (NRC). have?
